EMG
OCUL icon

ETF Managers Group’s Ocular Therapeutix OCUL Stock Holding History

ETF Managers Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-74,388
Closed -$1.19M – 762
2021
Q1 		$1.19M Buy
74,388
+14,592
+24% +$281K 0.02% 255
2020
Q4 		$1.22M Buy
+59,796
New +$888K 0.03% 228

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

ETF Managers Group's OCUL Position: Q2 2021 in Review

ETF Managers Group sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 74,388 shares — an estimated $1.19M sold.

ETF Managers Group first reported a position in OCUL in Q4 2020 and held it in 2 quarters. The position peaked at $1.22M in Q4 2020. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

  • ETF Managers Group reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 74,388 Ocular Therapeutix shares in Q2 2021, an estimated $1.19M.
  • ETF Managers Group first reported a position in Ocular Therapeutix in Q4 2020 and held it in 2 quarters.
  • ETF Managers Group's Ocular Therapeutix position peaked at $1.22M in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.